InsiderTrades

Form 4 for ANTX AN2 Therapeutics, Inc.

Accepted 2023-08-22 00:00:00 ET · period of report 2023-08-18 · accession 0001104659-23-094274 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
I 2023-08-22 2023-08-18 ANTX RA Capital Nexus Fund II, L.P. 10% P - Purchase $9.00 +1.78M 5.14M +53% +$16.00M

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2023-08-18 P A 1,777,778 $9.00 5,135,683 I See Footnotes — — (F1) Acquired from the Issuer pursuant to the public offering described in the Issuer's Prospectus filed with the Securities and Exchange Commission on August 16, 2023. (F3) Held directly by the Fund. (F2) RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.